NeuroVive Pharmaceutical AB Interim report January – March 2018
Successful rights issueBusiness operations Important events January – March 2018 · NeuroVive decided to conduct a rights issue for the continued development of the company’s drug projects following shareholder approval at an Extraordinary General Meeting. · The company reported positive efficacy data in an experimental model, entailing a breakthrough for the NVP025 mitochondrial myopathy project. · NeuroVive presented the company at the Stockholm Corporate Finance Life Science Seminar. · The company presented its NASH research at the 2nd Annual H.C. Wainwright NASH Investor